Let's talk medical research

Accelerating medical research is a mission that affects us all - and it takes a dialogue. We welcome you to join the conversation and share any thoughts or comments here.


Has Lung Cancer Met Its Match?

It takes at least 10 years and $2.6 billion on average for a new treatment to become available for the general population, which means that it is a big deal when critical medical advancements are made.1 It also means it’s a big deal when we take steps towards those medical advancements, which is why we’re…

Read more

A Moment of Hope: Why Now Is the Time to Get Involved in Lung Cancer Research

Jennifer King is the Director of Science and Research for our partner, the Lung Cancer Alliance. She holds a PhD in Molecular Biology from MIT, and spent several years in the lab doing translational, “bench to bedside” research. She then worked with the American Society of Clinical Oncology (ASCO) where she was able to expand…

Read more

Will you raise your hand?

I chose to join the Antidote team because I firmly believe in the organization’s mission: Driving medical research forward by connecting people to medical research. Shortly after I joined the team, I learned just how valuable those breakthroughs can be. One day last December, as I sat at my desk catching-up with my team members…

Read more

Lewy Body Dementia, Through a Researcher’s Eyes

Jim Leverenz is a neurologist by training, and he’s been studying Lewy body disease since the 1980’s. Dr. Leverenz is proud to be the Chair of the Lewy Body Dementia Association’s (LBDA) Scientific Advisory Council (SAC), a post he’s held for seven years. He’s been a part of the SAC for more than a decade,…

Read more

Introducing GALAXY, Featuring the Antidote Search Tool

Today is a big day here at Antidote. It’s official – our Alzheimer’s disease search is live with our partner, GALAXY! What’s GALAXY? It’s a new online portal that offers mobile tools and resources that make it easy for patients to influence and participate in Alzheimer’s disease research. What we love about it is that…

Read more

Bridging the Divide Between Patients and Industry

Earlier this week, we had the pleasure of attending the EyeforPharma Patient Summit in Philadelphia. The event was two days of industry experts and patients diving deep into how best how to navigate restrictive regulatory waters while engaging with patients in a meaningful way. Our eyes were opened to what’s working – and to the opportunities…

Read more
Benjamin Franc. Imaging dementia with PET-CT. Clinical Faculty University of California, San Francisco, via Brain Stories Blog.

An Urgent Call for Lewy Body Dementia Research

You may have read about Lewy Body dementia (LBD) in the news recently – it’s the illness that led to the death of Robin Williams, and also impacts nearly 1.5 million people in the United States, along with countless family members and caregivers. LBD refers to two diagnoses: Parkinson’s disease dementia and dementia with Lewy bodies.…

Read more

How Does Antidote Work?

There’s a lot of medical research information out there. It’s on dozens of websites, it’s written in free text, and usually, it’s riddled with jargon. You want to take part in a study, but you don’t have a medical degree – how are you supposed to figure out what might work? How are you meant…

Read more

Ten Things We Want You to Know About Clinical Trials

1. Clinical trials are the only way that new drugs are tested to ensure that they are safe and that they work. 2. Clinical trials have been around since the 1700’s, when James Lind tested whether citrus would help sailors with scurvy. 3. Today, each clinical trial goes through a rigorous approval process to ensure…

Read more

It’s World Alzheimer’s Day…Or, Why We Do What We Do

Today is a special day here at Antidote. Sure, it’s September 21 – but what that means is that it is World Alzheimer’s Day. This is a day on which, every year, Alzheimer’s organizations from around the world focus their efforts on raising Alzheimer’s and dementia awareness. We couldn’t be more proud to join our…

Read more

Hello, we’re Antidote

We’re excited to share some big news about TrialReach. As of today, TrialReach is now Antidote. Why? Because we’ve unveiled a completely new brand – one that’s building on what was special about TrialReach and taking it even further. There’s a problem you may have heard about. Today, 85% of patients don’t know about clinical…

Read more

Big Steps Forward: A Guest Post from ePatient Dave

For the past several years my business has been diversifying – in addition to speeches, workshops and policy meetings, I’ve spent an increasing amount of time as an advisor to startups. One of my favorite clients, the most successful so far, is TrialReach, about which I’ve written before, when they raised another round of financing in…

Read more
Antidote Icon

How It Works

We're organizing the world's research information to transform the way patients and researchers connect.

Antidote Icon


The Board's responsible for setting Antidote's strategic direction and overseeing our performance against our goals.

Antidote Icon


Antidote's making headlines.